Navigation Links
SUPERaseIn from Ambion

ProductsSUPERaseIn from Ambion
Company Ambion
Item SUPERaseIn
Price $92.00
Description SUPERaseIn RNase Inhibitor (patent pending) is a protein based inhibitor of nonhuman origin that noncovalently binds and inhibits the most common and troublesome RNases including RNase A, B, C, 1 and T1. SUPERaseIn can be used in any application where RNase contamination could be problematic. It is ideal for in vitro transcription and translation, cDNA synthesis, RT-PCR, and preparation of RNase-free antibodies. Because it inhibits a broader range of RNases than traditional RNase inhibitors, SUPERaseIn is the most effective RNase inhibitor available providing a higher level of protection against degradation.

The most widely used RNase inhibitor is placental ribonuclease inhibitor (RIP). SUPERaseIn is distinct from RIP in that it has a more robust interaction with RNases, does not release active RNases in the absence of DTT, and inhibits a broader range of RNases. While placental ribonuclease inhibitors are effective only against RNase A type enzymes, SUPERaseIn also inhibits RNase 1 and T1. SUPERaseIn does not interfere with other enzymes such as RNA polymerases, reverse transcriptase or Taq polymerase. Additionally, SUPERaseIn is active up to 65C and for a pH range of 5.5 to 8.5.

Info AmbionAmbion
2130 Woodward
Austin, TX 78744
USA

Call Ambion to buy products (US and Canada only; other locations use numbers below)
USA Canada 1-512-795-4221
Customer Service: 512-651-0200
Fax Number: 512-651-0201
Web Site: http://www.ambion.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. SUPERaseIn from Ambion
2. Silencer siRNA Starter Kit from Ambion
3. SlideHyb Glass Array Hybridization Buffer #1 from Ambion
4. mirVana™ miRNA Bioarray Essentials Kit from Ambion
5. SlideHyb Glass Array Hybridization Buffer #1 from Ambion
6. siPORT NeoFX Transfection Agent 1 ml from Ambion
7. siPORT NeoFX Transfection Agent from Ambion
8. DNase I (RNase-free) (2 U/l) from Ambion
9. TURBO DNase (2 U/l) from Ambion
10. Guanylyltransferase (5 U/l) from Ambion
11. 96 well Magnetic-Ring Stand 1 each from Ambion
... HT is designed for extended ... HT is ideal for applications ... primer extension assays. The iEMS ... a one-cabinet model, allowing the ...
... Source: Pseudomonas atlantica Description: Beta-Agarase is ... fragments from low-melting-temperature agarose. Beta-Agarase digests ... Tested User Friendly Properties: Heat Inactivation: ... Da Optimum pH: 6.5 Purity: Tested ...
iEMS Thermal Microplate Holder...
Improve inventory management with stainless steel red cell canisters; ensure product safety with CO2 or LN2 backup systems. A complete solution for your blood banking needs....
Biology Products:
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the ... 2015-2019" report to their offering. ... is the adoption of multimodal biometric systems. Multimodal ... an individual for verification and identification purposes. This ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... University (Canada) have teamed up with genome researchers from ... bone samples from Siberia. The project also involved ... and researchers from Russia, the United Kingdom, France, and ... sequences from a woolly mammoth will be published on ...
... the first solid evidence that still "sharp" older brains store ... discovery is reported by a Johns Hopkins team in the ... prove to apply as well to human brains, it could ... therapies based on what healthy older brains are doing, rather ...
... Unscripted biochemical variations, or noise, leads to oscillations in ... have debated for decades the relative importance of nature ... behaves, and now UCSD scientists report that noise could ... , In a paper in Proceedings of the National ...
Cached Biology News:Scientists sequence DNA of woolly mammoth 2'Sharp' older brains are not the same as younger brains 2Phenotype is influenced by nature, nurture and noise 2
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... 2014 The empty capsules market ... ageing population and technological innovations in the empty ... are catalysing the growth of the empty capsules ... , Scope of Report , The report ... new entrants/smaller firms to gauge the pulse of ...
(Date:12/19/2014)... 2014 Relmada Therapeutics, Inc. (OTCQB: RLMD), a ... chronic pain, announced the results of its annual general ... a transformational year in Relmada,s history and it set ... said Sergio Traversa , chief executive officer of ... key financial, human resource and clinical development objectives that ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8